[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05143307":3,"trial-entities:NCT05143307":89,"trial-summary:NCT05143307":93},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":38,"secondary_outcomes":43,"sex":44,"minimum_age":45,"maximum_age":15,"healthy_volunteers":46,"eligibility_criteria":47,"std_ages":53,"locations":56,"central_contacts":82,"overall_officials":83,"references":87,"see_also_links":88},"NCT05143307","EBT-101-002","Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101","Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Parent Study Where EBT-101 Was Administered","ENROLLING_BY_INVITATION","2037-04","2024-05","2024-05-14","2023-07-11","Excision BioTherapeutics","INDUSTRY",null,"Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).","Participants who receive EBT-101 in a parent protocol will be eligible to participate in this LTFU study (EBT-101-002). All participants will have follow-up visits every six months until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually on the anniversary of EBT-101 administration until study completion at Year 15.",[19],"HIV-1-infection",[21,22,23],"CRISPR","Gene Therapy","adeno-associated virus serotype 9 (AAV9)","INTERVENTIONAL","OTHER",[27],"PHASE1",{"count":29,"type":30},9,"ESTIMATED",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36},"BIOLOGICAL","EBT-101","Long term follow up of participants who received EBT-101",[37],"Long Term Follow Up",[39],{"measure":40,"description":41,"timeFrame":42},"Long-term safety of EBT-101","Long-term safety of EBT-101 will be assessed based on incidence and severity of clinically significant adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 15 years","15 years",[],"MALE","18 Years",false,{"inclusion":48,"exclusion":51,"raw_text":52},[49,50],"Willing and able to provide written, signed informed consent","Participants who received the investigational study intervention EBT-101 in a parent study",[],"Inclusion Criteria:\n\n* Willing and able to provide written, signed informed consent\n* Participants who received the investigational study intervention EBT-101 in a parent study\n\nExclusion Criteria:\n\n• Participants who did not receive EBT-101 in a parent study",[54,55],"ADULT","OLDER_ADULT",[57,66,74],{"facility":58,"city":59,"state":60,"zip":61,"country":62,"geoPoint":63},"Quest Clinical Research","San Francisco","California","94115","United States",{"lat":64,"lon":65},37.77493,-122.41942,{"facility":67,"city":68,"state":69,"zip":70,"country":62,"geoPoint":71},"Washington University","St Louis","Missouri","63110",{"lat":72,"lon":73},38.62727,-90.19789,{"facility":75,"city":76,"state":77,"zip":78,"country":62,"geoPoint":79},"Cooper Health","Camden","New Jersey","08103",{"lat":80,"lon":81},39.92595,-75.11962,[],[84],{"name":85,"affiliation":13,"role":86},"William Kennedy, MD","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":90,"biomarkers":92},[91],"HIV Infection",[],{"nct_id":4,"found":46,"summary":15,"prompt_version":15}]